Jie Da1, Pingping Liu1, Rong Wang1, Lijia Bu2. 1. Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, PR China. 2. Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, PR China. Electronic address: blj_ayfy@163.com.
Abstract
OBJECTIVES: To explore the expression level and to investigate the clinical associations of the long non-coding RNA (lncRNA) FAM83H-AS1 in gastric cancer. METHODS: The expression level of FAM83H-AS1 were explored by quantitative reverse transcription PCR (qRT-PCR). The Cox regression models as well as log-rank test were utilized to investigate whether FAM83H-AS1 expression could be used as a prognosis predictor. The value of FAM83H-AS1 as a diagnostic biomarker was evaluated by receiver operating curves (ROC). RESULTS: Aberrantly upregulation of FAM83H-AS1 was identified in gastric cancer in comparison with that in normal tissues. We also found that upregulated FAM83H-AS1 was a risk factor relating to OS and DFS. The area under curve (AUC) was 0.8603 and 0.6778 for gastric cancer and lymph node metastasis, respectively. CONCLUSION: Our results indicated that FAM83H-AS1 may function as an oncogene in gastric cancer and could be used as a prognosis predictor or diagnostic biomarker in gastric cancer.
OBJECTIVES: To explore the expression level and to investigate the clinical associations of the long non-coding RNA (lncRNA) FAM83H-AS1 in gastric cancer. METHODS: The expression level of FAM83H-AS1 were explored by quantitative reverse transcription PCR (qRT-PCR). The Cox regression models as well as log-rank test were utilized to investigate whether FAM83H-AS1 expression could be used as a prognosis predictor. The value of FAM83H-AS1 as a diagnostic biomarker was evaluated by receiver operating curves (ROC). RESULTS: Aberrantly upregulation of FAM83H-AS1 was identified in gastric cancer in comparison with that in normal tissues. We also found that upregulated FAM83H-AS1 was a risk factor relating to OS and DFS. The area under curve (AUC) was 0.8603 and 0.6778 for gastric cancer and lymph node metastasis, respectively. CONCLUSION: Our results indicated that FAM83H-AS1 may function as an oncogene in gastric cancer and could be used as a prognosis predictor or diagnostic biomarker in gastric cancer.